Match tier Likely match
Presence Current · Arkansas
Last published 2025
Sources OpenAlex · ORCID
Refreshed 2026-10-06

Hong Fang

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Role not yet determined Is this you? Add your title

Also affiliated: United States Food and Drug Administration (2001–2025); University of Health Sciences and Pharmacy (2025); Washington University in St. Louis (2025); Northrop Grumman (United States) (2004); ICF International (United States) (2008–2017); Procter & Gamble (United States) (2003); Zhejiang University (2010)

50 h-index 112 pubs 11,876 cited

  • Humans
  • Oligonucleotide Array Sequence Analysis
  • Animals
  • Drug-Related Side Effects and Adverse Reactions
  • Gene Expression Profiling
  • United States Food and Drug Administration
  • United States
  • Drug Labeling
  • Algorithms
  • Software
  • Rats
  • Quantitative Structure-Activity Relationship
  • Computational Biology
  • Toxicogenetics
  • Databases, Factual

Biography and Research Information

OverviewAI-generated summary

Hong Fang's research centers on the application and validation of molecular profiling technologies, particularly in the context of toxicological research and drug development. Fang was involved in the MicroArray Quality Control (MAQC) project, a significant initiative aimed at assessing the reproducibility and reliability of gene expression measurements across different platforms. This work led to publications in 2006 and 2010, focusing on inter- and intra-platform reproducibility and the development of predictive models using microarray data.

Further research has explored the concordance between different transcriptomic technologies, such as RNA-seq and microarrays, examining how factors like chemical treatment and transcript abundance influence their agreement, as detailed in a 2014 publication. Fang has also investigated structure-activity relationships for various chemical compounds, including natural, synthetic, and environmental estrogens and androgens, contributing to the understanding of potential toxicological effects. This includes work on chemicals binding to the androgen receptor and a focus on drug-induced liver injury, utilizing FDA-approved drug labeling information.

With a career marked by over 120 publications and a high citation count, Fang leads a research group at the National Center for Toxicological Research. Key collaborators include Leihong Wu, Joshua Xu, Weida Tong, and Lan Ying, all affiliated with the same institution. Fang's work emphasizes the development and validation of methodologies for robust biological data generation and interpretation.

Metrics

  • h-index: 50
  • Publications: 112
  • Citations: 11,876

Selected Publications

  • Leveraging FDA Labeling Documents and Large Language Model to Enhance Annotation, Profiling, and Classification of Drug Adverse Events with AskFDALabel (2025)
    Drug Safety 17 citations DOI OpenAlex
  • S02-03 FDALabel: enabling full text searching of drug labeling (2024)
    Toxicology Letters DOI OpenAlex
  • Description and Validation of a Novel AI Tool, LabelComp, for the Identification of Adverse Event Changes in FDA Labeling (2024)
    Drug Safety 9 citations DOI OpenAlex
  • Text summarization with ChatGPT for drug labeling documents (2024)
    Drug Discovery Today 18 citations DOI OpenAlex
  • RxBERT: Enhancing drug labeling text mining and analysis with AI language modeling (2023)
    Experimental Biology and Medicine 16 citations DOI OpenAlex
  • Artificial intelligence and real-world data for drug and food safety – A regulatory science perspective (2023)
    Regulatory Toxicology and Pharmacology 48 citations DOI OpenAlex
  • FDALabel for drug repurposing studies and beyond (2020)
    Nature Biotechnology 19 citations DOI OpenAlex
  • Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine (2020)
    Drug Discovery Today 58 citations DOI OpenAlex
  • Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA (2019)
    BMC Bioinformatics 81 citations DOI OpenAlex
  • Drug-Induced Liver Injury (DILI) Classification and Its Application on Human DILI Risk Prediction (2018)
    Methods in pharmacology and toxicology 6 citations DOI OpenAlex
  • Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans (2017)
    Archives of Toxicology 64 citations DOI OpenAlex
  • The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury (2017)
    Expert Review of Gastroenterology & Hepatology 62 citations DOI OpenAlex
  • Integrating Drug’s Mode of Action into Quantitative Structure–Activity Relationships for Improved Prediction of Drug-Induced Liver Injury (2017)
    Journal of Chemical Information and Modeling 34 citations DOI OpenAlex
  • Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases (2016)
    Trends in Pharmacological Sciences 13 citations DOI OpenAlex
  • FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science (2016)
    Drug Discovery Today 56 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

329 Collaborators 122 Institutions 16 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics